Group 1 - Shanghai Sunshine Pharmaceutical Procurement Network announced that starting from September 16, 2025, certain drug procurement qualifications will be suspended due to non-compliance with price adjustment requirements by some companies [1] - A total of 10 drugs, including 15 specifications, are affected, involving 11 companies such as Shutaishen and Sichuan Baili Pharmaceutical [1] - Shutaishen's product, Compound Polyethylene Glycol (3350) Quality Vitamin C Powder, is set to be launched on October 9, 2024, as the first domestic generic, aimed at bowel cleansing before medical procedures [1] Group 2 - Shutaishen has experienced a continuous revenue decline for three years and has reported losses for five consecutive years, accumulating over 1 billion yuan in losses [2] - In the first half of 2025, Shutaishen reported revenue of 126 million yuan, a year-on-year decline of 31.14%, with a net profit of -24.64 million yuan [2] - Sichuan Baili Pharmaceutical's oral solution of Enalapril Maleate is also included in the suspended procurement list, with Baili Pharmaceutical reporting revenue of 113 million yuan in the first half of 2025, accounting for 66% of its parent company's revenue [2] Group 3 - Other drugs affected by the procurement suspension include Vancomycin Capsules, Betamethasone Ointment, Calcium Acetate Oral Solution, and several others from various pharmaceutical companies [3]

证券时报·数据宝统计显示，舒泰神今日收盘价为38.14元，下跌1.01%，日换手率为4.54%，成交额为 7.89亿元，全天主力资金净流出7179.13万元，近5日该股累计下跌0.70%，近5日资金合计净流出3.33亿 元。 据天眼查APP显示，舒泰神(北京)生物制药股份有限公司成立于2002年08月16日。注册资本47777.2555 万人民币。（数据宝） 舒泰神9月16日大宗交易平台共发生9笔成交，合计成交量465.87万股，成交金额1.51亿元。成交价格均 为32.42元，相对今日收盘价折价15.00%。从参与大宗交易营业部来看，机构专用席位共出现在9笔成交 的买方或卖方营业部中，合计成交金额为1.51亿元，净买入1.51亿元。 进一步统计，近3个月内该股累计发生11笔大宗交易，合计成交金额为1.55亿元。 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 价（%） | 业部 | | | 123.87 | 4015.87 | 32.42 | ...

Summary of Key Points Core Viewpoint - The stock of Shuotai Shen experienced a decline of 1.01% on September 16, closing at 38.14 yuan, with significant block trades occurring totaling 4.6587 million shares and a transaction value of 151 million yuan [1][2]. Trading Activity - A total of 9 block trades were recorded, all at a price of 32.42 yuan per share, with a consistent discount of 15% from the market price [1][2]. - The first four trades involved 61,000 shares, 67,000 shares, 61,000 shares, and 91,500 shares respectively, with transaction values of approximately 19.78 million yuan, 21.72 million yuan, 19.78 million yuan, and 29.66 million yuan [1]. - The subsequent trades included 15,000 shares, 9,000 shares, 6,500 shares, 123,870 shares, and 31,000 shares, with transaction values ranging from approximately 210,000 yuan to 40.16 million yuan [2]. Recent Performance - Over the past three months, Shuotai Shen has seen a total of 11 block trades with a cumulative transaction value of 155 million yuan [3]. - In the last five trading days, the stock has decreased by 0.70%, with a net outflow of 309 million yuan in principal funds [3].

| 序号 | 统编代码 | 通用名 | 规格包装 | | --- | --- | --- | --- | | | | | 每袋A剂含聚乙二醇 | | | | 复方聚乙二醇 | 3350 100g、硫酸钠 | | | XA06ADF748P0 | | 7.500g、氯化钠 2.691g、 | | | 01010100233 | (3350)电解质 | 氯化钾 1.015g;每袋 B 剂 | | | | 维 C 散 | | | | | | 含维生素 C4. 700g、维生 | | | | | 素 C 钠 5. 900g。*2 袋/盒 | | --- | --- | --- | --- | | 2 | XA07AAW001E0 | 盐酸万古霉素 | 0.125g*20 粒/盒 | | | 01010184858 | 胶囊 | | | 3 | XA07AAWOO1EO | 盐酸万古霉素 | 0.125g*12 粒/盒 | | | 01010284858 | 胶囊 | | | 4 | XC09AAY074X0 | 马来酸依那普 | 150m1/瓶 | | | 01010102120 | 利口服溶液 | | | 5 | ...

Group 1 - The core point of the article highlights the recent decline in the stock price of Shutaishen, which fell by 5.02% to 38.43 CNY per share, with a trading volume of 1.195 billion CNY and a turnover rate of 6.71%, resulting in a total market capitalization of 18.361 billion CNY [1] - Shutaishen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue composition of Shutaishen includes: 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - From the perspective of major fund holdings, Huabao Fund has one fund heavily invested in Shutaishen, specifically Huabao Anying Mixed A (010868), which held 20,400 shares in the second quarter, accounting for 0.54% of the fund's net value, ranking as the eighth largest holding [2] - The estimated floating loss for Huabao Anying Mixed A today is approximately 41,400 CNY [2] - Huabao Anying Mixed A was established on June 8, 2021, with a current scale of 140 million CNY. Year-to-date returns are 9.09%, ranking 5991 out of 8246 in its category, while the one-year return is 15.93%, ranking 6375 out of 8054 [2]

Group 1 - The core point of the news is the performance and market position of Shutaishen (Beijing) Biopharmaceutical Co., Ltd., which saw a stock price increase of 5.06% to 41.71 CNY per share, with a trading volume of 1.532 billion CNY and a turnover rate of 8.45%, resulting in a total market capitalization of 19.928 billion CNY [1] - Shutaishen's main business involves the research, production, and sales of biological products and some chemical drugs, with the revenue composition being 59.17% from injectable mouse nerve growth factor (Sutai) and 33.19% from compound polyethylene glycol electrolyte powder [1] Group 2 - From the perspective of fund holdings, Changcheng Fund has a significant position in Shutaishen, with the Changcheng Health Life Mixed A Fund holding 328,900 shares, accounting for 3.57% of the fund's net value, making it the eighth largest holding [2] - The Changcheng Health Life Mixed A Fund has achieved a year-to-date return of 40.81% and a one-year return of 60.77%, ranking 1386 out of 8174 and 2045 out of 7981 in its category, respectively [2] Group 3 - The fund manager of Changcheng Health Life Mixed A is Tan Xiaobing, who has a tenure of 9 years and 225 days, with the fund's total asset size being 2.967 billion CNY [3] - During Tan's tenure, the best fund return was 176.09%, while the worst return was a loss of 28.66% [3]

9月9日，舒泰神股份有限公司（300204.SZ，下称"舒泰神"）发布公告称，公司拟向特定对象发行股票募资不超过12.53亿元，其中8.83亿元用 于创新药物研发项目，3.7亿元补充流动资金。 此次定增发生在公司募集资金账户余额告急之际。 财报显示，截至2023年12月31日，公司募集资金专户存储余额仅剩7.065万元。在创新药研发的关键阶段，资金补给迫在眉睫。 具体来看，舒泰神是一家创新型生物制药企业，公司致力于研发、生产和销售临床治疗需求未被满足的治疗性药物，当前，公司研发管线聚焦 于四大领域，分别为感染性疾病、呼吸与重症、自身免疫系统疾病及神经系统疾病。 目前9个I类创新生物药多项适应症正处于临床试验阶段，此次募资的8.83亿元研发资金将主要用于推进这些核心项目。此前，公司指出，将集 中资源推进临床阶段成药性明确的研发项目，加快创新药上市。 根据公告内容，本次发行股票数量不超过公司发行前总股本的30%，即上限为1.43亿股。发行价格将不低于定价基准日前20个交易日公司股票 交易均价的80%，最终以中国证监会注册批复为准。 资金分配方案显示，88%的募集资金将投入研发（8.83亿元），剩余3.7亿元用于补 ...

Core Points - The company Shuyou Shen announced the election of Mr. Zheng Hong as the employee representative director of the sixth board of directors [2] - The election took place during the employee representative meeting held on September 10, 2025 [2] - Mr. Zheng Hong's qualifications meet the relevant legal and regulatory requirements [2] - He will join the board of directors elected by the shareholders to form the sixth board, serving until the term of the sixth board expires [2]

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于舒泰神（北京）生物制药股份有限公司 2025 年第一次临时股东会的法律意见书 康达股会字【2025】第 0383 号 致：舒泰神（北京）生物制药股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 股东会规则》（以下简称"《规则》"）、《深圳证券交易所上市公司股东会网 络投票实施细则》（以下简称"《实施细则》"）、《舒泰神（北京）生物制药 股份有限公司章程》（以下简称"《公司章程》"）及舒泰神（北 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-066 舒泰神（北京）生物制药股份有限公司 关于选举产生第六届职工代表董事的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 郑宏先生： 1971 年 07 月出生，中国国籍，无境外永久居留权，大学本科学历，经济学 学士学位；1994 年至 2001 年，在江苏汇鸿国际集团土产进出口股份有限公司从 事总账会计工作；2001 年至 2005 年，在江苏先声药业有限公司任财务总监；2006 年至 2009 年，在江苏新港医药有限公司任销售管理中心副总监；2010 年至今， 在舒泰神（北京）生物制药股份有限公司历任财务总监、商务总监、运营总监、 监察总监等工作；2021 年 08 月至 2025 年 09 月任本公司职工监事。 郑宏先直接持有公司股份 11.50 万股，未与持有公司 5%以上股份的其他股 东、公司其他董事、高级管理人员存在关联关系。郑宏先生作为公司职工代表董 事候选人，不存在受到中国证监会及其他有关部门的处罚和证券交易所惩戒的情 形，不存在《公司法》《公司章程》中规定的不得担任公司职工 ...